The management of patients with atrial fibrillation (AF) who have undergone drug-eluting stent (DES) implantation for ≥1 year presents a significant clinical dilemma. Balancing the risk of stroke against the risk of bleeding from antithrombotic therapy is paramount. Therefore, new data from the ADAPT AF-DES trial offers powerful evidence to simplify this complex treatment regimen. This study demonstrates that NOAC monotherapy AF stent patients is noninferior and, importantly, clinically superior to continuing dual antithrombotic therapy with a NOAC plus clopidogrel.
Evaluating NOAC Monotherapy in AF Stent Patients
The ADAPT AF-DES trial, a multicenter, open-label, randomised study, enrolled patients with AF at least one year after DES implantation. Consequently, researchers compared NOAC monotherapy (apixaban or rivaroxaban) against NOAC plus clopidogrel. The primary outcome was a composite of net adverse clinical events (NACE) at 12 months, including death, ischemic events, and bleeding. Importantly, the trial successfully met its noninferiority endpoint, proving that the single-agent NOAC strategy did not compromise safety or efficacy. Moreover, a prespecified superiority analysis demonstrated a significant benefit in NACE reduction for the monotherapy group. This robust finding supports a shift in post-PCI management for stable AF patients.
The Critical Reduction in Bleeding Risk
The major driver for the observed superiority was a dramatic decrease in bleeding events. For example, the incidence of major or clinically relevant non-major bleeding was substantially lower in the NOAC monotherapy group (5.2%). This contrasts sharply with the dual antithrombotic therapy group (13.2%). Such a reduction is highly significant, because this complication often leads to transfusions, hospitalisation, or even death. Consequently, this finding is particularly impactful for clinicians who balance bleeding and thrombosis risk daily. Conversely, the rates of ischemic events—including myocardial infarction, stroke, and stent thrombosis—were comparable between the two treatment arms. Therefore, discontinuing clopidogrel after the initial stable period (generally 12 months post-DES) provides a strong safety advantage. It also maintains necessary ischemic protection for the patient.
Frequently Asked Questions
Q1: What was the primary finding of the ADAPT AF-DES trial?
NOAC monotherapy was noninferior to NOAC plus clopidogrel for a composite of net adverse clinical events (NACE) in AF patients at least one year after drug-eluting stent (DES) implantation.
Q2: What benefit did NOAC monotherapy offer over dual therapy?
The monotherapy strategy achieved superiority, primarily driven by a significant reduction in major or clinically relevant non-major bleeding compared to the dual antithrombotic regimen.
Q3: Did NOAC monotherapy increase the risk of ischemic events?
No, ischemic outcomes, including all-cause death, stroke, myocardial infarction, and stent thrombosis, were comparable between the NOAC monotherapy and dual antithrombotic therapy groups, suggesting no loss of ischemic protection.
References
- Mukherjee D et al. In AF with drug-eluting stent for ≥1 y, NOACs were noninferior to NOAC + clopidogrel for a composite of adverse clinical events at 1 y. Ann Intern Med. 2026 Feb 03. doi: 10.7326/ANNALS-25-05478-JC. PMID: 41628468.
- Kim J-S, et al. NOAC Monotherapy Non-Inferior to Combination Therapy for Net Adverse Clinical events in AF Patients Post–DES: ADAPT AF-DES Trial. Cardiology Now News. Accessed February 4, 2026.
- Lee SY, et al. NOAC Monotherapy vs NOAC Plus Clopidogrel for Atrial Fibrillation in DES Patients (ADAPT AF-DES). PCRonline.com. Accessed February 4, 2026.
- Lampert J, Kim J-S. Oral anticoagulation alone preferable in stable patients with atrial fibrillation, stent. Healio. Accessed February 4, 2026.